capecitabine has been researched along with er-086526 in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 9 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| O'Shaughnessy, JA; Perez, EA; Rugo, HS | 2 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Beegle, N; Blau, S; Cox, D; Dranitsaris, G; Faria, C; Kalberer, T | 1 |
| Adachi, Y; Aoshima, K; Asano, M; Funahashi, Y; Kawano, S; Kimura, T; Matsui, J; McCracken, PJ; Nomoto, K; Oda, Y; Okamoto, K; Ozawa, Y; Semba, T; Tizon, X; Tohyama, O; Uehara, T; Uesugi, M; Watanabe, H | 1 |
| Awada, A; Cortes, J; He, Y; Kaufman, PA; Olivo, M; Twelves, C; Vahdat, L | 1 |
| Cox, D; Dranitsaris, G; Faria, C; Gluck, S; Rugo, H | 1 |
| Awada, A; Cortes, J; Dutcus, CE; He, Y; Kaufman, PA; Olivo, MS; Perez, EA; Twelves, C; Velikova, G; Yelle, L | 1 |
| Berrak, E; Hoffman, AD; Jones, VE; McIntyre, K; O'Shaughnessy, J; Smith, JW; Song, JX; Vukelja, S | 1 |
| Awada, A; Cortes, J; Forsythe, A; Hudgens, S; Kaufman, PA; McCutcheon, S; Perez, EA; Twelves, C; Velikova, G; Yelle, L | 1 |
| Awada, A; Binder, TA; Cortes, J; Jove, M; Kaufman, PA; O'Shaughnessy, JA; Olivo, M; Perez, EA; Song, J; Twelves, C; Yelle, L | 1 |
| Li, J; Ren, J; Sun, W | 1 |
| Domchek, SM | 1 |
| Bae, S; Banchereau, J; Banchereau, R; Blankenship, D; Brookes, HM; Cepika, AM; Chung, CH; George, J; Kim, KI; Lavecchio, E; Levin, MK; Marches, F; Martinek, J; O'Shaughnessy, J; Obermoser, G; Oxley, KL; Palucka, AK; Pascual, V; Smith, JL; Snipes, GJ; Turner, J; Wang, X; Wu, TC; Xu, K; Young, RR; Zurawski, S | 1 |
| Armstrong, A; Bannister, W; Conte, P; Degboe, A; Delaloge, S; Domchek, SM; Goessl, C; Hettle, R; Im, SA; Li, W; Masuda, N; Robson, M; Ruddy, KJ; Senkus, E; Tung, N; Xu, B | 1 |
| Goessl, C; Im, SA; Iwata, H; Li, W; Masuda, N; Ouyang, Q; Park, YH; Robson, M; Sohn, JH; Tseng, LM; Wu, W; Xu, B; Yeh, DC | 1 |
| Chatterjee, D; Hauser, R; Kaufman, PA; Kazmi, S; Raju, D | 1 |
| Ko, Y; Kuo, CN; Lin, YJ | 1 |
| Goodwin, A; Im, SA; Kim, SB; Lanzalone, S; Lee, KH; Sohn, J; Usari, T | 1 |
| Artacho Criado, S; Díaz-Acedo, R; Galván Banqueri, M; Gutiérrez Pizarraya, A; Jiménez Galán, R; Marcos Rodríguez, JA; Márquez Saavedra, E; Rodríguez-de-la-Borbolla-Artacho, M | 1 |
| Kojima, Y; Nishikawa, T; Noguchi, E; Okuya, T; Satomi-Tsushita, N; Shimoi, T; Sudo, K; Sumiyoshi-Okuma, H; Takamizawa, S; Tanioka, M; Yazaki, S; Yonemori, K | 1 |
| Altundag, K | 1 |
| Drier, SW; Ekwueme, DU; Fairley, TL; Gogate, A; Reeder-Hayes, KE; Rocque, GB; Rotter, J; Trogdon, JG; Wheeler, SB | 1 |
| Burn, O; Dunton, K; Hancock, E; Paine, A; Petrou, M; Vondeling, G | 1 |
1 review(s) available for capecitabine and er-086526
| Article | Year |
|---|---|
Systematic review of ixabepilone for treating metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Administration Schedule; Epothilones; Female; Furans; Humans; Ketones; Paclitaxel; Survival Analysis; Treatment Outcome | 2017 |
10 trial(s) available for capecitabine and er-086526
| Article | Year |
|---|---|
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids | 2014 |
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Taxoids; Young Adult | 2015 |
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Feasibility Studies; Female; Furans; Humans; Ketones; Middle Aged; Neoplasm Staging; Postmenopause | 2016 |
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Female; Furans; Humans; Ketones; Middle Aged; Quality of Life | 2015 |
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Furans; Humans; Ketones; Prognosis | 2015 |
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Topics: Animals; Breast Neoplasms; Capecitabine; CD11c Antigen; Cell Line, Tumor; Cell Membrane; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Ketones; Leukocytes, Mononuclear; Macrophages; Mice; Mice, SCID; Myeloid Cells; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Pilot Projects; Transcription, Genetic; Transforming Growth Factor beta | 2018 |
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Furans; Germ-Line Mutation; Humans; International Agencies; Ketones; Male; Middle Aged; Neoplasm Metastasis; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate; Time-to-Treatment; Vinorelbine; Young Adult | 2019 |
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Breast Neoplasms; Capecitabine; Carcinoma; Female; Furans; Gastrointestinal Diseases; Genes, BRCA1; Genes, BRCA2; Genes, erbB-2; Germ-Line Mutation; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Single-Blind Method; Vinorelbine | 2020 |
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asia; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Furans; Gemcitabine; Germ-Line Mutation; Humans; Ketones; Middle Aged; Phthalazines; Prognosis; Receptor, ErbB-2; Survival Rate; Vinorelbine | 2021 |
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2; Vinorelbine | 2022 |
13 other study(ies) available for capecitabine and er-086526
| Article | Year |
|---|---|
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2011 |
Current treatment options for metastatic breast cancer: what now?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Tubulin Modulators | 2011 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Community Mental Health Centers; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Medical Oncology; Middle Aged; Retrospective Studies; Vinblastine; Vinorelbine | 2015 |
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Topics: Animals; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Mice, Inbred BALB C; Tubulin Modulators; Tumor Microenvironment; Vascular Remodeling; Xenograft Model Antitumor Assays | 2014 |
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Cytotoxins; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine | 2018 |
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Liver; Lung Neoplasms; Retrospective Studies; Survival Analysis | 2020 |
Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Drug Costs; Female; Furans; Health Care Costs; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Quality of Life; Taiwan; Treatment Outcome | 2021 |
Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Furans; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2022 |
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Female; Furans; Humans; Ketones; Leukocyte Count; Middle Aged; Prognosis; Retrospective Studies | 2022 |
Combination Treatment of Vinorelbine With Oral Cyclophosphamide or Capecitabine or Both Might Overcome Cross-resistance Against Eribulin in Advanced Breast Cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Fluorouracil; Furans; Humans; Ketones; Treatment Outcome; Vinblastine; Vinorelbine | 2022 |
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Paclitaxel; Quality of Life; Taxoids | 2023 |